The 20% reduction in cardiovascular events seen in the SELECT trial may not be entirely explained by weight loss
Nabeh OA
As the regulatory landscape surrounding GLP-1 medications continues to evolve, healthcare providers, patients, and compounding pharmacies must navigate a complex intersection of medical need, legal boundaries, and public health priorities
GLP-1 injections are medications that imitate a naturally occurring hormone in the body known as Glucagon-Like Peptide-1 (GLP-1)
At this point in the disease course, even meaningful shifts in fluid biomarkers may not translate into measurable improvements in cognition or daily functioning over a two-year trial, Koychev stated
European Journal of Endocrinology / European Federation of Endocrine Societies , 146 (6), 863869.